In the News / Politics

FDA Regulatory Change Expands Access to Mifepristone

By: Ashley Dao, PharmD Candidate c/o 2024 Medical abortion is approved by the Food and Drug Administration (FDA) to end…

3 years ago

New Study Expands Pharmacists’ Role in Treating Opioid Use Disorder

By: Geraldine Ciaccio, PharmD Candidate c/o 2025 ​The role of pharmacists in public health has been expanding in recent years.…

3 years ago

The 1980’s HIV and AIDS Epidemic

By: Christian Porcu, PharmD Candidate c/o 2024 and John Ortiz, PharmD Candidate c/o 2025 Human immunodeficiency virus (HIV) impairs immune…

3 years ago

Evaluating Treatments and Preventative Measuresfor Monkeypox

By: Sairah Sheikh, PharmD Candidate c/o 2024 ​              As Coronavirus Disease 2019 (COVID-19) cases started to decrease in the United…

3 years ago

FDA Approval of Pemazyre® as a First-in-Class Treatment forMyeloid / Lymphoid Neoplasms with FGFR1 Rearrangement

By: Jennifer Galvet, PharmD Candidate c/o 2024               Fibroblast growth factor receptors (FGFRs) are a family of receptor tyrosine kinases…

3 years ago

Relyvrio: A New FDA-Approved Medication for Amyotrophic Lateral Sclerosis

By: Yu Jeng Lee, PharmD Candidate c/o 2023               Amyotrophic lateral sclerosis (ALS), also referred to as Lou Gehrig’s disease,…

3 years ago

Evaluating the Risk of Neurodevelopmental Disorders from Antidepressant Use During Pregnancy

By: Geraldine Ciaccio, PharmD Candidate c/o 2025 ​              Pregnant women treated with antidepressants may no longer have to endure the…

4 years ago

AstraZeneca’s Farxiga is First Heart Failure Drug to Show Across-the-Board Mortality Benefit

By: Jennifer Galvet, PharmD Candidate c/o 2024               Farxiga (dapagliflozin) is a first-in-class, oral, once daily sodium-glucose cotransporter 2 (SGLT2)…

4 years ago

Pediatric COVID-19 Immunization Schedules Updated with Bivalent Booster Vaccines

By: Helen Li, PharmD Candidate c/o 2023               On June 18, 2022, Centers for Disease Control and Prevention (CDC) Director,…

4 years ago

FDA Approves Tzield (teplizumab-mzwv) to Delay Onset of Type 1 Diabetes

By: Justin Budz, PharmD Candidate c/o 2023               Diabetes mellitus encompasses both chronic and reversible conditions that affect the body’s…

4 years ago